

**Soy Protein, Isoflavones, and Cardiovascular Health : An American Heart Association
Science Advisory for Professionals From the Nutrition Committee**

Frank M. Sacks, Alice Lichtenstein, Linda Van Horn, William Harris, Penny Kris-Etherton and
Mary Winston

Circulation. 2006;113:1034-1044; originally published online January 17, 2006;
doi: 10.1161/CIRCULATIONAHA.106.171052

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://circ.ahajournals.org/content/113/7/1034>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>

Soy Protein, Isoflavones, and Cardiovascular Health An American Heart Association Science Advisory for Professionals From the Nutrition Committee

Frank M. Sacks, MD; Alice Lichtenstein, DSc; Linda Van Horn, PhD, RD; William Harris, PhD;
Penny Kris-Etherton, PhD; Mary Winston, EdD;
for the American Heart Association Nutrition Committee

Abstract—Soy protein and isoflavones (phytoestrogens) have gained considerable attention for their potential role in improving risk factors for cardiovascular disease. This scientific advisory assesses the more recent work published on soy protein and its component isoflavones. In the majority of 22 randomized trials, isolated soy protein with isoflavones, as compared with milk or other proteins, decreased LDL cholesterol concentrations; the average effect was $\approx 3\%$. This reduction is very small relative to the large amount of soy protein tested in these studies, averaging 50 g, about half the usual total daily protein intake. No significant effects on HDL cholesterol, triglycerides, lipoprotein(a), or blood pressure were evident. Among 19 studies of soy isoflavones, the average effect on LDL cholesterol and other lipid risk factors was nil. Soy protein and isoflavones have not been shown to lessen vasomotor symptoms of menopause, and results are mixed with regard to soy's ability to slow postmenopausal bone loss. The efficacy and safety of soy isoflavones for preventing or treating cancer of the breast, endometrium, and prostate are not established; evidence from clinical trials is meager and cautionary with regard to a possible adverse effect. For this reason, use of isoflavone supplements in food or pills is not recommended. Thus, earlier research indicating that soy protein has clinically important favorable effects as compared with other proteins has not been confirmed. In contrast, many soy products should be beneficial to cardiovascular and overall health because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low content of saturated fat. (*Circulation*. 2006;113:1034-1044.)

Key Words: AHA Scientific Statements ■ cardiovascular diseases ■ soybean proteins ■ isoflavones ■ cholesterol

Soy protein has gained considerable attention for its potential role in improving risk factors for cardiovascular disease (CVD). In October 1999, the US Food and Drug Administration (FDA) approved labeling for foods containing soy protein as protective against coronary heart disease.¹ The FDA based this decision on clinical studies showing that at least 25 g of soy protein per day lowered total and LDL cholesterol. The FDA requires for the claim that a serving contain at least 6.25 g of soy protein, 25% of the necessary daily amount (25 g), with the expectation that foods containing soy protein would be eaten at least 4 times per day. The FDA also stated that “the evidence did not support a significant role for soy isoflavones in cholesterol-lowering effects of soy protein.”¹

In 2000, the American Heart Association (AHA) Nutrition Committee released a scientific advisory on soy protein and

CVD.² At that time, the conclusion was that “it is prudent to recommend including soy protein foods in a diet low in saturated fat and cholesterol.” Since then, many well-controlled studies on soy protein and soy-derived isoflavones substantially added to the knowledge base. For this reason, the AHA Nutrition Committee decided to reevaluate the evidence on soy protein and CVD and update its scientific advisory. Thus, this scientific advisory assesses the more recent work published on soy protein and its component isoflavones. The focus is on blood LDL cholesterol because it is by far the most studied risk factor for CVD, is the primary criterion on which the National Cholesterol Education Program estimates risk and recommends therapy,³ and forms the basis for the FDA-approved health claim. In this advisory, we also consider the effects of soy protein and isoflavones on several other CVD risk factors: HDL cholesterol, triglycer-

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on August 10, 2005. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0279. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kramsay@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit <http://www.americanheart.org/presenter.jhtml?identifier=3023366>.

© 2006 American Heart Association, Inc.

Circulation is available at <http://www.circulationaha.org>

DOI: 10.1161/CIRCULATIONAHA.106.171052

ides, lipoprotein(a), and blood pressure. The medical literature was searched comprehensively for original research publications on the effects of soy protein or isoflavones on CVD risk factors, and all controlled trials that separately listed soy protein and isoflavone content were used. In addition, this advisory reviews the evidence on soy products in other health conditions, including menopausal symptoms, osteoporosis, and cancer.

Soy protein, like any other dietary protein, contains calories and could be used in the diet to replace animal protein or other vegetable proteins. Soy protein also could replace other sources of calories such as carbohydrate or fat, raising the total amount of protein eaten and reducing carbohydrate or fat intake. Most studies exchanged soy protein for other dietary proteins, and this evidence is evaluated in the present advisory. Much less is known about the potential impact on risk factors for CVD of increasing total protein intake by adding soy or other plant protein in place of carbohydrate or fat; this important dietary change is currently being studied.

The Soy Protein Hypothesis on LDL Cholesterol

An Overview

Animal proteins raise blood cholesterol concentrations in several animal species fed cholesterol-free semisynthetic diets.^{4,5} Casein, the most prevalent protein in milk, has been used most often, although other animal proteins such as pork and beef protein do the same. This is a useful established nutritional model for studying diet-induced hypercholesterolemia and atherosclerosis and an alternative to feeding animals large amounts of cholesterol. In contrast, when soy protein is substituted for the animal protein, hypercholesterolemia does not occur. Thus, either some animal proteins have a direct hypercholesterolemic action, or soy protein has a cholesterol-lowering action. This latter possibility led to intensive work in the late 1970s and 1980s to test the hypothesis that soy protein can be a nutritional approach to reducing blood cholesterol. This concept gained support from epidemiological observations on diet and CVD in Japan and other Asian countries where large amounts of soy products were eaten and blood cholesterol concentration and CVD incidence were low.⁶ However, many differences in diet and lifestyle between Asian and Western countries could explain the differences in the prevalence of CVD.

Early indications that soy protein had much less effect in humans than in animals came from direct application of the animal model to humans. Diets similar to those eaten by humans, based on either soy protein or casein, were fed to rabbits, and, as expected, casein produced hypercholesterolemia.⁷ However, when the same diets were fed to healthy people, the protein source did not affect blood cholesterol.^{7,8} Others studied the effect of casein in strict vegetarians who ate no dairy or animal proteins to provide a human counterpart to the mainly vegetarian animal (eg, rabbit) models. Compared with soy protein, no effect of casein on blood cholesterol was found.⁹

In the late 1970s and early 1980s, the soy protein hypothesis was greatly strengthened as a result of studies by Sirtori

et al¹⁰ and Descovich et al,¹¹ who found that diets high in soy protein, replacing nearly all the animal protein, substantially reduced blood LDL cholesterol by 20% to 30% in severe hypercholesterolemia. Because the soy protein diets were also reduced in saturated fat and cholesterol and increased in polyunsaturated fat and because the patients also often lost weight on the dietary protocols, the results were often confounded. The authors reported that textured soy protein (50% soy flour, 50% soy protein concentrate) but not soy protein isolate (90% soy protein) was effective. This raised the possibilities that, rather than the soy protein itself, the nonprotein components of the soy protein preparation or the effect of soy displacing cholesterol-raising fats in the diet could have had a blood cholesterol-lowering action. Results of other early studies of soy protein in hypercholesterolemic subjects showed either cholesterol reduction¹² or no effect.^{13,14}

A meta-analysis published in 1995 attempted to reconcile the many divergent findings among studies of soy protein.¹⁵ In 29 controlled studies, a trend emerged that soy protein selectively reduced blood cholesterol in direct proportion to the degree of hypercholesterolemia. For example, in those with severely elevated blood cholesterol (>335 mg/dL), soy protein reduced blood cholesterol by 20%. Only a 7% reduction occurred in those with cholesterol levels between 259 and 333 mg/dL; if the initial blood cholesterol was <255 mg/dL, there was no significant effect. Thus, the response to soy protein was determined more by the initial blood cholesterol level and, surprisingly, not by the amount of soy protein eaten, which ranged widely from 18 to 124 g/d. When the control group was not included in the statistical analysis, there was a significant correlation between the dose of soy protein and the degree of cholesterol reduction. However, an analysis without a control group introduces the effects of confounding and drift in serum cholesterol that often occur in experimental situations. This meta-analysis also was limited by the quality of the studies; studies were less well controlled in people with hypercholesterolemia than in those with average cholesterol levels. It is difficult to determine how much effect this had on the overall results of the meta-analysis. Thus, the available literature provided some support, albeit with limitations, for the concept that soy protein is an effective treatment for severe hypercholesterolemia, that it produces a mild benefit in people with moderate elevations of cholesterol, but that it has no effect in those with mildly elevated or average cholesterol levels. The soy protein hypothesis culminated in FDA approval of a health claim for soy protein in foods.

Soy Isoflavones

Subsequent to the meta-analysis by Anderson et al,¹⁵ many well-controlled studies explored the soy protein hypothesis with greater specificity. In addition, recognition that soy protein products contain bioactive molecules called phytoestrogens or isoflavones added a fascinating new aspect to the soy protein hypothesis.^{16,17,18} Isoflavones remain in soy protein preparations that are not extracted with alcohol. During the preparation of soy protein isolate, the soy is washed with alcohol, removing a substantial amount of the

isoflavones. The soy isoflavones have strong biological properties in animals, causing arterial vasodilation, lowering serum cholesterol,¹⁸ and inhibiting atherosclerosis in postmenopausal monkeys.¹⁹ This led to the intriguing idea that the presence and amount of isoflavones explain the variable results of soy studies; only those that used high-isoflavone preparations produced favorable results.^{18,20} Isoflavone content was not known in many of the earlier studies. Several subsequent studies tested the effects of soy protein and isoflavones separately.

The 3 major isoflavones found in soybeans are genistin, daidzin, and glycitin. Their abundance in soy protein preparations varies widely and depends on the processing techniques used during production.^{21,22} These compounds have both estrogenic and antiestrogenic activity^{23,24} and effects that are unrelated to estrogen activity.²⁵ Dehulling, flaking, and defatting soybeans produces a relatively pure preparation of protein that is low in isoflavones,^{26,27} whereas methods used to produce textured soy protein result in a preparation that retains the isoflavones.²¹ Isoflavone concentrations range from ≈ 2 mg/g protein in textured soy protein, soy flour, and soy granules to 0.6 to 1.0 mg/g protein in isolated soy protein. Intakes of 45 g soy flour have resulted in a 20- to 40-fold increase and a 50- to 100-fold increase in blood and urinary isoflavones, respectively,²⁸ and there is a dose-dependent relationship at more moderate intakes.²⁹

Effect of Soy Protein on LDL Cholesterol and Other Lipoproteins

Soy Protein With Isoflavones

First, we summarize studies that tested soy protein that contained a substantial amount of isoflavones. Because it was recognized that isoflavones could be the bioactive component attributed to soy protein, studies published in the late 1990s and beyond generally stated the amount and type of isoflavones in the soy protein. In 22 randomized trials, isolated soy protein with isoflavones was compared with casein or milk protein,^{20,30–46} wheat protein,⁴⁷ or mixed animal proteins.^{48–50} The range of soy protein was 25 to 135 g/d; the range for isoflavones was 40 to 318 mg. LDL or non-HDL cholesterol concentrations decreased in most studies, statistically significantly in 8, with an overall effect of $\approx 3\%$ (weighted average). A recent meta-analysis that included 10 studies published from 1995 to 2002 found a similar percentage reduction in LDL cholesterol with no dose effect.⁵¹ Over all studies in Table 1, there is no apparent dose effect; the 8 studies with 50 g of soy protein showed a drop in LDL cholesterol concentration similar to those using a smaller amount of soy, $\approx 3\%$ overall (Table 1). This cutpoint for daily soy protein intake, 50 g, defines a large amount, half or more of the daily average total protein intake in the United States. No significant effects were evident for HDL cholesterol or triglycerides in most of the studies; the weighted average effects were very small: 1.5% for HDL cholesterol and -5% for triglycerides.

Soy Protein Without Isoflavones

In 7 trials, soy protein, washed with alcohol to remove isoflavones, was compared with casein or milk pro-

tein^{20,33,39,43,52} or various animal proteins (Table 2).^{49,50} Two studies showed small significant decreases in LDL cholesterol.^{49,50} These studies were very carefully controlled feeding studies, with all meals formulated according to strict nutritional specifications, and complete meals were provided to the participants.^{49,50} Specifically designed to sort out the effects of the protein from the effects of the isoflavones, the studies showed an effect of protein but not isoflavones on LDL cholesterol. The declines in LDL cholesterol were small, 2% to 7%, relative to the large amounts of soy protein eaten daily, 50 to 55 g. However, other well-controlled studies did not find significant effects of soy protein on LDL cholesterol,^{20,33,39,43,52} and the average change across all 7 studies was only a 1% to 2% decrease. Changes in HDL cholesterol and triglycerides were generally small and were nonsignificant in 6 of the 7 trials. No dose effect was evident.

Effect of Isoflavones

Some studies compared soy protein that did or did not contain isoflavones (Table 3),^{20,30,33,39,43,49,50,52–57} whereas other studies tested isoflavones in pill form as compared with placebo.^{58–63} A wide range of isoflavone amounts was studied. One study compared the effect of isoflavones provided with either soy or animal proteins.⁴⁹ Among these 19 studies,^{20,30,33,39,43,49,50,52–63} only 3 showed significant reductions in LDL cholesterol concentration,^{52,55,56} and the effect among all studies (weighted average) was nil, 0%. Changes in HDL cholesterol and triglycerides were not significant and showed no trend toward an effect of isoflavones. Despite large increases in blood isoflavone concentrations, there is no indication of a dose effect on blood lipids. A recent meta-analysis concluded that isoflavones do not affect blood lipid concentrations.⁵¹

Influence of Initial Blood LDL Cholesterol Level

In the Anderson et al¹⁵ meta-analysis, a strong gradient of LDL cholesterol reduction was found among studies according to initial cholesterol level. Lichtenstein et al⁴⁹ and Crouse et al²⁰ found slightly more LDL cholesterol reduction in people with LDL cholesterol >160 to 164 mg/dL than in those with lower levels, although Dent et al³³ did not find an effect in women with hypercholesterolemia as compared with women with average cholesterol levels. However, a larger percentage reduction in LDL cholesterol in hypercholesterolemia is not evident among the 22 recent trials (Table 1). Among studies of isoflavones, no relation is evident between initial cholesterol and cholesterol lowering (Table 3).

Influence of Serum Cholesterol-Lowering Diet

In their meta-analysis, Anderson et al¹⁵ reported that soy protein tended to have less effect on LDL cholesterol in trials in which the participants were eating a low-fat and low-cholesterol diet as compared with a more usual higher-fat and higher-cholesterol diet. In 11 of the studies listed in Tables 1 through 3, soy protein or isoflavones were tested in combination with a serum cholesterol-lowering diet.^{20,30,31,34,42,45,47,48,50,58,60} The average reduction in LDL in these studies was 2%, similar to that in the full group. Thus, the effect on LDL of soy protein or isoflavones does not appear to be modulated by the saturated fat and cholesterol content of the diet.

TABLE 1. Soy Protein and Blood Lipid Risk Factors: Effects of Soy Protein With Isoflavones

Study and Year	Reference	n	Type	Age, y	Design	Dose	Duration	Base TC, mg/dL	TC, %	LDL, %	HDL, %	TG, %	Comments
West et al 2005	45	32	M, F, HC	58	X, DB	ISP 25 g IF 90 vs milk protein	6 wk	250	↑ 1 (NS)	0	↑ 1 (NS)	↑ 5 (NS)	
Kreijkamp-Kaspers et al 2004	44	88	F, HC	67	Para, DB	ISP 26 g + IF 99 mg vs milk protein	12 mo	240	↑ 2 (NS)	↑ 4 (NS)	↑ 3 (NS)	↓ 8 (NS)	
Steinberg et al 2003	43	28	F, NI	55	X, DB	ISP 25 g + IF 107 mg vs milk protein	6 wk	190	↓ 4 (NS)	↓ 3 (NS)	↓ 7 (NS)	↑ 6 (NS)	
Cuevas et al 2003	42	18	F, HC	59	X, DB	ISP 40 g + IF 80 mg vs casein	4 wk	285	↓ 1 (NS)	0	↑ 4 (NS)	↓ 15 (NS)	
Blum et al 2003	37	24	F, HC	55	X, DB	ISP 25 g + IF 85 mg vs milk prot	6 wk	270	↑ 1 (NS)	↑ 4 (NS)	↓ 4 (NS)	↓ 1 (NS)	
Dalais et al 2003	38	38	F, HC	60	Para, DB	ISP 40 g + IF 118 mg vs casein	3 mo	236	↓ 4 (NS)	↓ 6*	↑ 7 (NS)	↓ 26*	
Jenkins et al 2002	50	41	M, F, HC	62	X	ISP 50 g + IF 73 mg vs dairy + egg protein	1 mo	260	↓ 4*	↓ 6*	↑ 2 (NS)	↑ 2 (NS)	
Tonstad et al 2002	46	30	M, F, HC	52	Para	ISP 30–50 g + IF 111–185 mg vs casein	16 wk	270	↓ 4*	↓ 5*	↑ 3 (NS)	↓ 3 (NS)	No dose effect
Meinertz et al 2002	39	12	M, F, NI	30	X	ISP 133 g + IF 318 mg vs casein	32 d	164	↑ 8 (NS)	↓ 2 (NS)	↑ 10*	↑ 12 (NS)	Liquid diets
Lichtenstein et al 2002	49	42	M, 18; F, 24	63	X	F: ISP 55 g + IF 108 mg; M: ISP 71 g + IF 139 mg vs dairy and meat protein	6 wk	236	↑ 1 (NS)	↑ 4 (NS)	↑ 3*	↓ 7*	
Sirtori et al 2002	41	20	M, F, HC	60	X, DB	Soy 25 g + IF 77 mg vs cow's milk	4 wk	325	↓ 3 (NS)	↓ 4 (NS)	ND	ND	
Puska et al 2002	36	30	HC	56	Para, DB	ISP 52 g + IF 192 mg vs casein	6 wk	290	↓ 3*	↓ 5*	↑ 1 (NS)	↑ 3 (NS)	
Dent et al 2001	33	24	F	50	Para	ISP 40 g + IF 80 mg vs milk protein	24 wk	220	No effect on lipids; numerical data not shown				
Van Horn et al 2001	34	62	F, HC	67	Para	ISP 29 g + IF 85 mg vs milk protein	6 wk	240	0	↓ 1 (NS)	↑ 1 (NS)	ND	
Teede et al 2001	35	90	M, F	61	Para, DB	ISP 40 g w/IF 118 mg vs casein	3 mo	225	↓ 2 (NS)	↓ 4 (NS)	↑ 5 (NS)	↓ 15*	
Hermansen et al 2001	40	20	DM	64	X, DB	ISP 50 g + IF 165 mg vs casein	6 wk	212	↓ 8	↓ 10*	0	↓ 9*	
Vigna et al 2000	32	40	F, Postmen	53	Para, DB	ISP 60 g + IF 76 mg vs casein	12 wk	240	0	↓ 1 (NS)	↑ 2 (NS)	↓ 1 (NS)	
Jenkins et al 2000	47	25	M, F, HC		X	ISP 36 g + IF 168 mg vs wheat protein	3 wk	270	↓ 2 (NS)	↓ 1 (NS)	↓ 2 (NS)	↓ 6 (NS)	
Teixeira et al 2000	31	16	M, HC	45	Para	ISP 50 g + IF 95 mg vs casein 50 g ISP 20 g + IF 38 mg vs casein 50 g	6 wk	240	↓ 7* ↓ 5*	Non-HDL ↓ 9* Non-HDL ↓ 7*	↑ 2 (NS) ↑ 2 (NS)	↑ 8 (NS) ↑ 1 (NS)	No dose effect from 20–50 g
Crouse et al 1999	20	30	M, F	52	Para, DB	ISP 25 g + IF 62 mg vs casein	9 wk	240	↓ 4*	↓ 6*	0 (NS)	↑ 9 (NS)	No effect in LDL <164 mg/dL group
Wong et al 1998	48	26	HC, 13 NI, 13	38	X	ISP 50 g + IF vs mixed animal	5 wk	270	↓ 3	↓ 6*	↑ 3	↑ 6 (NS)	IF content not specified
Baum et al 1998	30	21	F, Postmen	61	Para, DB	ISP 40 g + IF 90 mg vs casein	24 wk	250	↓ 2 NS	Non-HDL ↓ 4*	↑ 4*	↑ 1 (NS)	

TC indicates total cholesterol; TG, triglycerides; M, male; F, female; HC, hypercholesterolemic; DM, diabetes mellitus; NI, normolipidemic; DB, double blind; X, crossover; Para, parallel group; ISP, isolated soy protein; IF, isoflavones; NS, not significant ($P>0.05$); and ND, not determined. Percentages are the mean change in soy protein minus the change in the control group.

* $P<0.05$ for effect of soy protein vs other protein.

Effects on Lipoprotein(a)

Lipoprotein(a), an LDL-like lipoprotein that is an independent predictor of CVD,⁶⁴ was increased by soy protein in 2 studies^{35,65} and unchanged in 9 others.^{20,31,32,36,40,44–46,50} Meinertz et al³⁹ found that alcohol-extracted soy protein, lacking isoflavones, did not raise lipoprotein(a) as found in their earlier study of intact soy protein,⁶⁵ which suggests an adverse effect of isoflavones. However, isoflavones had no

effect on lipoprotein(a) in 6 other studies,^{20,50,55,60,61,63} nor did soy protein that contained isoflavones.^{20,31,32,36,40,44–46,50}

Effects on Blood Pressure

Several studies tested the effect of soy protein with isoflavones, as compared with casein or milk protein, on blood pressure.^{32,35,40,42,47,50} Blood pressure decreased significantly in 1 study³⁵ but not in the other 5 studies.^{32,40,42,47,50} The

TABLE 2. Effects of Soy Protein With Low or No Isoflavones

Study and Year	Reference	n	Type	Age, y	Design	Dose, g	Duration	Base TC, mg/dL	TC, %	LDL, %	HDL, %	TG, %
Steinberg et al 2003	43	28	F, NI	55	X,DB	ISP 25 vs milk protein	6 wk	190	↓ 2 (NS)	↓ 2 (NS)	↓ 4 (NS)	↑ 10 (NS)
Jenkins et al 2002	50	41	M, F, HC	62	X	ISP 50 vs dairy and egg protein	1 mo	260	↓ 6*	↓ 7 (NS)	↑ 2 (NS)	↓ 10 (NS)
Lichtenstein et al 2002	49	42	M, F	63	X	ISP 55 F; 71 M vs dairy and meat protein	6 wk	236	↑ 1 (NS)	↑ 3 (NS)	↑ 3%*	↓ 14*
								280	↓ 3*	↓ 5*	0	↓ 11 (NS)
Meinertz et al 2002	39	12	M, F, NI	30	X	ISP 133 vs casein liquid diets	32 d	164	↑ 4 (NS)	↑ 4 (NS)	↑ 6 (NS)	↑ 11 (NS)
Dent et al 2001	33	24	F	50	Para	ISP 40 vs milk protein	24 wk	220	No effect on lipids (data not shown)			
Gardner et al 2001	52	31	F, Postmen	60	Para	ISP 42 vs casein	12 wk	240	↑ 3 (NS)	↑ 5 (NS)	↑ 7 (NS)	↓ 8 (NS)
Crouse et al 1999	20	30	M, F	52	Para,DB	ISP 25 vs casein	9 wk	240	↓ 2 (NS)	↓ 2 (NS)	↓ 4 (NS)	↓ 1 (NS)
High LDL group >164 mg/dL								260	↓ 4 (NS)	↓ 5 (NS)	↑ 5 (NS)	↑ 21 (NS)

Abbreviations as in Table 1. Percentages are the mean change in the soy protein minus the change in the control group.

* $P < 0.05$ for effect of soy protein vs other protein.

weighted average change is -1 mm Hg systolic blood pressure. Several studies that evaluated the effect of soy isoflavones also did not find a significant effect on blood pressure.^{50,58,60,62,66}

Effects on Health Conditions Related to Estrogens

Menopausal Vasomotor Symptoms

Because of their weak estrogenic activity, soy isoflavones have been hypothesized to improve several estrogen-dependent conditions, including perimenopausal vasomotor symptoms (hot flashes) and postmenopausal bone loss. A recent review examined 11 clinical trials of soy protein or isoflavones⁶⁷ for treating hot flashes. Only 3 of 8 studies with treatment lasting >6 weeks found modest improvement in hot flashes, and most benefits disappeared after 6 weeks. Five additional studies^{68–72} not included in that review showed no benefit for hot flashes of soy isoflavones. Longer studies showed no benefit of isoflavones at 24 weeks⁷³ or 2 years.⁷¹ Substantial reduction in hot flashes, often 40% to 60%, occurred in the placebo or control group in these studies, similar to the reduction in the soy group. In contrast, estrogen replacement markedly reduces hot flashes, more so than placebo. Thus, it seems unlikely that soy isoflavones have enough estrogenic activity to have an important impact on vasomotor symptoms of estrogen deficiency in perimenopausal women.

Osteoporosis

Another estrogenic effect of soy isoflavones could be to reduce bone loss after menopause; this hypothesis gains strength from population studies and certain animal models of osteoporosis.⁷⁴ However, clinical trials so far have had insufficient duration and size to be conclusive, and results have varied.^{44,74} The studies used either direct measurements of bone mineral content and density in the spine and hip or

biochemical indices of bone resorption or formation to test the effect of soy isoflavones ranging in amount from 54 to 300 mg, but most studies used 80 to 110 mg. Soy isoflavones lessened bone loss over 6 to 24 months in some studies,^{75–78} whereas other trials did not show a benefit over the same duration.^{44,57,79} There is also inconsistency in the studies showing favorable effects, with one study showing benefit in the spine but not hip⁷⁵ and another showing the opposite,⁷⁷ or improvement in bone mineral content but not bone mineral density.^{76,77} Diminution of bone loss, indicated by a reduction in biochemical markers of bone resorption, was found in some studies^{78,80,81} but not in others.^{38,44,53,55,82,83} The amounts of isoflavones were similar in studies that found favorable or no effects. The longest study in any primate species was in postmenopausal monkeys (*cynomolgus macaques*); after 3 years, soy isoflavones did not slow bone loss, whereas estrogen replacement increased bone mineral content and density, as expected.⁸⁴ These varied results of clinical trials suggest the need for investigations of isoflavones and bone health that have substantial sample size and long duration to provide a definitive result.

Cancer

The weak estrogenic action of soy isoflavones and other phytoestrogens suggested the possibility that they could lessen the deleterious effects of more potent endogenous estrogens on breast and endometrial cancer. This hypothesis came from the low incidence of breast and endometrial cancers in Asian countries where soy products are prevalent in the diet and from certain animal models of breast and endometrial cancer showing benefit of soy isoflavones.^{85–87} In reality, a host of complexities have emerged that make it impossible to state a clinical recommendation for the use of soy isoflavones. In epidemiological studies, associations varied between intake of soy foods and isoflavones and incidence of breast cancer^{85,88–90}; some showed protective associations, and others showed no association.^{85,88–90} Clinical

TABLE 3. Effects of Isoflavones

Study and Year	Reference	n	Type	Age, y	Design	Dose, mg	Duration	Base TC, mg/dL	TC, %	LDL, %	HDL, %	TG, %
Nikander et al 2004	63	56	F, NI	55	X, DB	IF 117 vs 0 pills	3 mo	226	↑ 1 (NS)	↑ 9 (NS)	↓ 1 (NS)	↑ 1 (NS)
Gallagher et al 2004	57	17	F, NI	55	Para, DB	IF 96 vs 4; w/ISP IF 52 vs 4; w/ISP	9 mo	218	↑ 1 (NS) 0	↑ 3 (NS) ↑ 3 (NS)	↑ 3 (NS) ↓ 2 (NS)	↓ 14 (NS) ↓ 17 (NS)
Steinberg et al 2003	43	28	F, NI	55	X, DB	IF 107 vs 2; w/ISP	6 wk	190	↓ 2 (NS)	0	↓ 4 (NS)	↓ 4 (NS)
Jenkins et al 2002	50	41	M, F, HC	62	X, DB	IF 73 vs 10; w/ISP	1 mo	260	↑ 2 (NS)	↓ 1 (NS)	↓ 2 (NS)	↑ 20 (NS)
Lichtenstein et al 2002	49	42	M, F	63	X	IF 108–139 vs 0 w/ISP or animal protein	6 wk	236 280	↑ 1 (NS) ↓ 3*	↑ 3 (NS) ↓ 2 (NS)	↑ 1 (NS) ↓ 2 (NS)	↑ 4 (NS) ↑ 2 (NS)
Squadrito et al 2002	58	30	F, Postmen	56	Para, DB	IF 54 vs 0 pills	6 mo	207	↑ 2 (NS)	↑ 5 (NS)	↓ 8 (NS)	↑ 26 (NS)
Sanders et al 2002	54	22	M, F, NI	30	X	IF 56 vs 0; w/ISP	2 wk	170	↑ 2 (NS)	0	↑ 4*	↑ 6 (NS)
Dewell et al 2002	59	20	F, Postmen	70	Para, DB	IF 150 vs 0 pills	6 mo	263	0	Non-HDL ↓ 6 (NS)	0	↓ 5 (NS)
Meinertz et al 2002	39	12	M, F, NI	30	X	IF 318 vs 0; w/ISP	32 d	164	↑ 4 (NS)	↓ 6 (NS)	↑ 4 (NS)	↑ 26*
Dent et al 2001	33	24	F	50	Para	IF 80 vs 0; w/ISP	24 wk	220	All NS (data not shown)			
								>220	All NS (data not shown)			
Gardner et al 2001	52	31	F, Postmen	60	Para	IF 80 vs 0; w/ISP	12 wk	240	↓ 3*	↓ 8*	0	0
Wangen et al 2001	55	18	F, Postmen	57	X	IF 65 vs 7; w/ISP IF 132 vs 7; w/ISP	3 mo	215	↓ 2 (NS) ↓ 3 (NS)	↓ 5 (NS) ↓ 6*	↑ 2 (NS) ↑ 1 (NS)	↑ 5 (NS) ↑ 5 (NS)
Mackey et al 2000	53	25	F, Postmen	56	Para, DB	IF 65 vs 4; w/ISP	12 wk	285	0	↓ 1 (NS)	↓ 2 (NS)	↑ 6 (NS)
Merz-Demlow et al 2000	56	13	F, Premen	26	X	IF 129 vs 10; w/ISP IF 65 vs 10; w/ISP	3 mo	150	NS All NS	↓ 7*	0	0
Simons et al 2000	60	20	F, Postmen	59	X, DB	IF 80 vs 0 pills	8 wk	228	↓ 1 (NS)	↓ 2 (NS)	↓ 1 (NS)	↑ 5 (NS)
Crouse et al 1999	20	30	M, F	52	Para, DB	IF 62 vs 3; w/ISP	9 wk	240	↓ 4 (NS)	↓ 5 (NS)	↑ 4 (NS)	↓ 10 (NS)
High LDL group >164 mg/dL								260	↓ 6*	↓ 6 (NS)	↓ 1 (NS)	↓ 9 (NS)
Baum et al 1998	30	21	F, Postmen	61	Para, DB	IF 90 vs 56; w/ISP	24 wk	250	0	Non-HDL 0	↓ 4 (NS)	↑ 1 (NS)
Hodgson et al 1998	61	30	M,F, Postmen	56	Para, DB	IF 55 vs 0 pills	8 wk	210	↓ 1 (NS)	↓ 3 (NS)	↓ 1 (NS)	↑ 5 (NS)
Nestel et al 1997	62	21	F, Postmen	54	X	IF 80 vs 0 pills	5 wk	215	↑ 2 (NS)	↑ 2 (NS)	↓ 5 (NS)	↑ 18 (NS)

Abbreviations as in Table 1, plus Premen indicates premenopausal. Percentages are the mean change in the isoflavone minus the change in the control group. *P<0.05 for isoflavone effect.

studies suggested that soy phytoestrogens stimulate epithelial cell proliferation in breasts of premenopausal women, a potential precursor of cancer.^{91,92} Animal and cell culture experiments also found a cancer-stimulating effect.^{93–95} Phytoestrogens reduce the activity of enzymes that inactivate endogenous estrogens, potentially leading to increased active estrogen concentrations.⁹⁶ Nonlinear dose effects, unique effects of specific types of isoflavones, changes in isoflavone composition and structure during the processing of soy foods, and interperson variation in isoflavone metabolism all could affect cancer initiation and progression^{22,86,87} and are virtually unexplored in the clinical arena. It has been hypothesized from animal experiments that soy isoflavones could be protective throughout adult life only if eaten in childhood or puberty.⁹⁷ Case-control studies in Shanghai⁹⁸ and in Asian Americans⁹⁹ found that high soy intake in adolescence was associated with low risk for breast cancer in adulthood. Finally, several recent expert reviews and editorials concluded that the research overall remains insufficient to know whether certain phytoestrogens are protective or harmful for breast cancer and at what dose and time period, if any, in a woman's life they are active.^{87,100,101}

Concepts with regard to soy isoflavones and breast cancer are applicable to uterine endometrial cancer, an estrogen-dependent cancer, although data are much less extensive. Soy food or isoflavone intake was associated with low risk for

endometrial cancer in case-control studies in Shanghai,¹⁰² Hawaii,¹⁰³ and California.¹⁰⁴ This suggests that soy phytoestrogens have antiestrogenic effects on the uterus. However, a single pilot trial of soy isoflavones given together with estrogen to perimenopausal or postmenopausal women found no lessening of estrogen-mediated stimulation of the endometrium.¹⁰⁵ Several clinical trials found that isoflavones did not affect the uterine endometrium of perimenopausal or postmenopausal women.^{105–110} However, these trials may have had insufficient duration (3 to 6 months) or sample size to identify an effect. Recently, a relatively large placebo-controlled trial in postmenopausal women found that isoflavone tablets caused endometrial hyperplasia, a precursor to cancer, after 5 years in 6 of 154 women compared with none on placebo (*P*<0.05).¹¹¹ Another 5 women in the phytoestrogen group had proliferative endometrium compared with none in the placebo group after 5 years. These effects were not found at 2½ years. Thus, some cautionary evidence indicates that soy phytoestrogens have enough estrogenic activity to stimulate the endometrium of postmenopausal women, although the evidence overall is inadequate to draw conclusions on whether soy protein or isoflavones taken by perimenopausal or postmenopausal women eventually would cause endometrial cancer.

Soy isoflavones have estrogenic, antiandrogenic, and other activities that could prevent prostate cancer or slow its

TABLE 4. Nutrient Content of Popular Soy-Containing Foods

Food Item	Quantity	Calories, kcal	Carbohydrates, g	Protein, g	Total Fat, g	Saturated Fat, g	Polyunsaturated Fat, g	n-3 Fatty Acids, g	n-6 Fatty Acids, g	Monounsaturated Fat, g	Cholesterol, mg	Sodium, mg	Dietary Fiber, g
Edamame	1/2 cup, 90 g	126	10	11	5	0.5	3	0.5	2.5	1.5	0	225	4
Miso	2 Tbsp, 34 g	71	10	4	2	0.5	1.1	0.1	1	0.5	0	1200	2
Tofu, extra firm	79 g	80	2	8	4	0.5	2.5	0.5	2	1	0	0	1
Tofu, firm	79 g	70	2	7	3	0.5	2	0.5	1.5	0.5	0	0	<1
Tofu, silken	91 g	45	2	4	2.5	0.5	1.5	0.5	1	0.5	0	5	0
Soy burger	1 patty, 57 g	60	6	13	0	0	0	0	0	0	0	270	3
Soy hot dog	1 link, 42 g	45	2	9	0	0	0	0	0	0	0	320	1
Roasted soy butter	2 Tbsp, 32 g	170	10	6	11	1.5	6	NA	NA	2.5	0	170	1
Soy milk, plain flavor	1 cup, 240 mL	100	8	7	4	0.5	2.5	0.5	2	1	0	120	1
Soy milk, chocolate	1 cup, 240 mL	140	23	5	3.5	0.5	2	0.2	1.8	1	0	100	2
Soy candy bar, chocolate	1 bar, 61.5 g	240	35	14	5	3	NA	NA	NA	NA	0	210	2
Soy nuts, roasted, unsalted	1 oz, 28 g	120	9	12	4	0	NA	NA	NA	NA	0	10	5

NA indicates not available. Values derived from Nutritionist Pro, version 2.10.13, First DataBank, Inc, 2004.

progression.^{86,87,112,113} Prostate cancer incidence is relatively low in Asian countries where soy products are commonly eaten, and certain epidemiological studies have shown an inverse association between soy foods, serum phytoestrogen levels, and prostate cancer.^{113,114} However, as pointed out by Messina,¹¹³ the epidemiological findings are inconsistent, and there are important limitations in study design. Soy isoflavones prevent the development and growth of prostate cancer in animal models. In prostate cancer cells, genistein reduced the synthesis of prostate-specific antigen, a marker of prostate cancer development and progression that is in extensive clinical use.⁸⁶ However, soy isoflavones did not reduce either prostate-specific antigen or serum testosterone levels in men with early-stage prostate cancer^{112,115,116} or in healthy middle-aged men.¹¹⁷ Thus, the effectiveness of soy isoflavones in preventing or treating human prostate cancer is unknown.

Conclusions

Earlier research indicating that soy protein, as compared with other proteins, has clinically important favorable effects on LDL cholesterol and other CVD risk factors has not been confirmed by many studies reported during the past 10 years. A very large amount of soy protein, more than half the daily protein intake, may lower LDL cholesterol by a few percentage points when it replaces dairy protein or a mixture of animal proteins. The evidence favors soy protein rather than soy isoflavones as the responsible nutrient. However, at this time, the possibility cannot be ruled out that another

component in soybeans could be the active factor. No benefit is evident on HDL cholesterol, triglycerides, lipoprotein(a), or blood pressure. Thus, the direct cardiovascular health benefit of soy protein or isoflavone supplements is minimal at best. Soy protein or isoflavones have not been shown to improve vasomotor symptoms of menopause, and results are mixed with regard to the slowing of postmenopausal bone loss. The efficacy and safety of soy isoflavones for preventing or treating cancer of the breast, endometrium, and prostate are not established; evidence from clinical trials is meager and cautionary with regard to a possible adverse effect. For this reason, use of isoflavone supplements in food or pills is not recommended. In contrast, soy products such as tofu, soy butter, soy nuts, or some soy burgers should be beneficial to cardiovascular and overall health because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low content of saturated fat¹¹⁸ (Table 4). Using these and other soy foods to replace foods high in animal protein that contain saturated fat and cholesterol may confer benefits to cardiovascular health.¹¹⁹ Soy protein also may be used to increase total dietary protein intake and to reduce carbohydrate or fat intake. However, much less is known about the potential impact of high-protein diets on risk factors for CVD. In the meantime, these remain dynamic areas for research. The AHA will continue to monitor the results and modify its advisory statement as needed.

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Penny Kris-Etherton	Pennsylvania State University	None	None	None	None	None	None
William Harris	St Luke's Hospital	None	None	None	None	None	None
Alice Lichtenstein	Tufts University	None	None	None	None	None	None
Frank Sacks	Harvard School of Public Health	None	None	None	None	None	None
Linda Van Horn	Northwestern University	None	None	None	None	None	None
Mary Winston	Consultant	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire that all authors are required to complete and submit.

Reviewers' Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Lori Mosca	Columbia University	None	None	None	None	None	None
Neil J. Stone	Northwestern University	None	None	None	None	None	None
Sheila West	Pennsylvania State University	None	None	Alpro, Inc	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Reviewer Disclosure Questionnaire that all reviewers are required to complete and submit.

References

- Food labeling: health claims: soy protein and coronary heart disease. Food and Drug Administration, HHS: final rule: soy protein and coronary heart disease. *Fed Reg*. 1999;64:57700–57733.
- Erdman JW Jr. AHA Science Advisory: soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. *Circulation*. 2000;102:2555–2559.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486–2497.
- Kritchevsky D. Vegetable protein and atherosclerosis. *J Am Oil Chemists Soc*. 1979;56:135–140.
- Carroll KK. Hypercholesterolemia and atherosclerosis: effects of dietary protein. *Fed Proc*. 1982;41:2792–2796.
- Keys A. *Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease*. Cambridge, Mass: Harvard University Press; 1980.
- van Raaij JM, Katan MB, Hautvast JG, Hermus RJ. Effects of casein versus soy protein diets on serum cholesterol and lipoproteins in young healthy volunteers. *Am J Clin Nutr*. 1981;34:1261–1271.
- van Raaij JM, Katan MB, West CE, Hautvast JG. Influence of diets containing casein, soy isolate, and soy concentrate on serum cholesterol and lipoproteins in middle-aged volunteers. *Am J Clin Nutr*. 1982;35:925–934.
- Sacks FM, Breslow JL, Wood PG, Kass EH. Lack of an effect of dairy protein (casein) and soy protein on plasma cholesterol of strict vegetarians: an experiment and a critical review. *J Lipid Res*. 1983;24:1012–1020.
- Sirtori CR, Gatti E, Mantero O, Conti F, Agradi E, Tremoli E, Sirtori M, Fraterrigo L, Tavazzi L, Kritchevsky D. Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia. *Am J Clin Nutr*. 1979;32:1645–1658.
- Descovich GC, Ceredi C, Gaddi A, Benassi MS, Mannino G, Colombo L, Cattin L, Fontana G, Senin U, Mannarino E, Caruzzo C, Bertelli E, Fragiaco C, Nosedà G, Sirtori M, Sirtori CR. Multicentre study of soybean protein diet for outpatient hyper-cholesterolaemic patients. *Lancet*. 1980;2:709–712.
- Goldberg AP, Lim A, Kolar JB, Grundhauser JJ, Steinke FH, Schonfeld G. Soybean protein independently lowers plasma cholesterol levels in primary hypercholesterolemia. *Atherosclerosis*. 1982;43:355–368.
- Holmes WL, Rubel GB, Hood SS. Comparison of the effect of dietary meat versus dietary soybean protein on plasma lipids of hyperlipidemic individuals. *Atherosclerosis*. 1980;36:379–387.
- Shorey RL, Bazan B, Lo GS, Steinke FH. Determinants of hypocholesterolemic response to soy and animal protein-based diets. *Am J Clin Nutr*. 1981;34:1769–1778.
- Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. *N Engl J Med*. 1995;333:276–282.
- Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. *Ann Med*. 1997;29:95–120.
- Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. *Am J Med*. 2002;113(suppl 9B):71S–88S.
- Anthony MS, Clarkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. *Am J Clin Nutr*. 1998;68:1390S–1393S.
- Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. *J Clin Endocrinol Metab*. 2001;86:41–47.
- Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitols M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. *Arch Intern Med*. 1999;159:2070–2076.
- Anderson RL, Wolf WJ. Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. *J Nutr*. 1995;125:581S–588S.
- Erdman JW Jr, Badger TM, Lampe JW, Setchell KD, Messina M. Not all soy products are created equal: caution needed in interpretation of research results. *J Nutr*. 2004;134:1229S–1233S.

23. Mikscek RJ. Estrogenic flavonoids: structural requirements for biological activity. *Proc Soc Exp Biol Med*. 1995;208:44–50.
24. Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. *Br J Nutr*. 1995;74:587–601.
25. Barnes S. Soy isoflavones: phytoestrogens and what else? *J Nutr*. 2004;134:1225S–1228S.
26. Dwyer JT, Goldin BR, Saul N, Gualtieri L, Barakat S, Adlercreutz H. Tofu and soy drinks contain phytoestrogens. *J Am Diet Assoc*. 1994;94:739–743.
27. Lusas EW, Riaz MN. Soy protein products: processing and use. *J Nutr*. 1995;125:573S–580S.
28. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. *J Endocrinol*. 1994;142:251–259.
29. Karr SC, Lampe JW, Hutchins AM, Slavin JL. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. *Am J Clin Nutr*. 1997;66:46–51.
30. Baum JA, Teng H, Erdman JW Jr, Weigel RM, Klein BP, Persky VW, Freels S, Surya P, Bakht RM, Ramos E, Shay NF, Potter SM. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. *Am J Clin Nutr*. 1998;68:545–551.
31. Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman JW Jr, Hasler CM. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. *Am J Clin Nutr*. 2000;71:1077–1084.
32. Vigna GB, Pansini F, Bonaccorsi G, Albertazzi P, Donega P, Zanotti L, De Aloysio D, Mollica G, Fellin R. Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. *Nutr Metab Cardiovasc Dis*. 2000;10:315–322.
33. Dent SB, Peterson CT, Brace LD, Swain JH, Reddy MB, Hanson KB, Robinson JG, Alekel DL. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. *J Nutr*. 2001;131:2280–2287.
34. Van Horn L, Liu K, Gerber J, Garside D, Schiffer L, Gernhofer N, Greenland P. Oats and soy in lipid-lowering diets for women with hypercholesterolemia: is there synergy? *J Am Diet Assoc*. 2001;101:1319–1325.
35. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. *J Clin Endocrinol Metab*. 2001;86:3053–3060.
36. Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT. Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial. *Eur J Clin Nutr*. 2002;56:352–357.
37. Blum A, Lang N, Vigder F, Israeli P, Gumanovsky M, Lupovitz S, Elgazi A, Peleg A, Ben-Ami M. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. *Clin Invest Med*. 2003;26:20–26.
38. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. *Clin Endocrinol (Oxf)*. 2003;58:704–709.
39. Meinertz H, Nilausen K, Hilden J. Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein(a) markedly. *Arterioscler Thromb Vasc Biol*. 2002;22:312–316.
40. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. *Diabetes Care*. 2001;24:228–233.
41. Sirtori CR, Bosisio R, Pazzucconi F, Bondioli A, Gatti E, Lovati MR, Murphy P. Soy milk with a high glycine content does not reduce low-density lipoprotein cholesterol in type II hypercholesterolemic patients. *Ann Nutr Metab*. 2002;46:88–92.
42. Cuevas AM, Iribarra VL, Castillo OA, Yanez MD, Germain AM. Isolated soy protein improves endothelial function in postmenopausal hypercholesterolemic women. *Eur J Clin Nutr*. 2003;57:889–894.
43. Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ. Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. *Am J Clin Nutr*. 2003;78:123–130.
44. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *JAMA*. 2004;292:65–74.
45. West SG, Hilperly KF, Juturu V, Bordi PL, Lampe JW, Mousa SA, Kris Etherton PM. Effects of including soy protein in a blood cholesterol lowering diet on markers of cardiac risk in men, and postmenopausal women +/- hormone replacement therapy. *J Womens Health (Larchmt)*. 2005;14:253–262.
46. Tonstad S, Smerud K, Hoie L. A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. *Am J Clin Nutr*. 2002;76:78–84.
47. Jenkins DJ, Kendall CW, Vidgen E, Vuksan V, Jackson CJ, Augustin LS, Lee B, Garsetti M, Agarwal S, Rao AV, Cagampang GB, Fulgoni V 3rd. Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein. *Metabolism*. 2000;49:1496–1500.
48. Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. *Am J Clin Nutr*. 1998;68:1385S–1389S.
49. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, Ausman LM. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. *Arterioscler Thromb Vasc Biol*. 2002;22:1852–1858.
50. Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen E, Cunnane SC, Leiter LA, Josse RG. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. *Am J Clin Nutr*. 2002;76:365–372.
51. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. *Eur J Clin Nutr*. 2003;57:940–946.
52. Gardner CD, Newell KA, Cherin R, Haskell WL. The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women. *Am J Clin Nutr*. 2001;73:728–735.
53. Mackey R, Ekangaki A, Eden JA. The effects of soy protein in women and men with elevated plasma lipids. *Biofactors*. 2000;12:251–257.
54. Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. *Am J Clin Nutr*. 2002;76:373–377.
55. Wangen KE, Duncan AM, Xu X, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. *Am J Clin Nutr*. 2001;73:225–231.
56. Merz-Demlow BE, Duncan AM, Wangen KE, Xu X, Carr TP, Phipps WR, Kurzer MS. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. *Am J Clin Nutr*. 2000;71:1462–1469.
57. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. *Menopause*. 2004;11:290–298.
58. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, Caputi AP, Squadrito G. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. *Atherosclerosis*. 2002;163:339–347.
59. Dewell A, Hollenbeck CB, Bruce B. The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. *J Clin Endocrinol Metab*. 2002;87:118–121.
60. Simons LA, von Konigsmark M, Simons J, Celemajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. *Am J Cardiol*. 2000;85:1297–1301.
61. Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Croft KD. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. *J Nutr*. 1998;128:728–732.
62. Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A, Abbey M. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. *Arterioscler Thromb Vasc Biol*. 1997;17:3392–3398.
63. Nikander E, Tiitinen A, Laitinen K, Tikkanen M, Ylikorkala O. Effects of isolated isoflavonoids on lipids, lipoproteins, insulin sensitivity, and ghrelin in postmenopausal women. *J Clin Endocrinol Metab*. 2004;89:3567–3572.
64. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. *Clin Chem*. 2003;49:1785–1796.
65. Nilausen K, Meinertz H. Lipoprotein(a) and dietary proteins: casein lowers lipoprotein(a) concentrations as compared with soy protein. *Am J Clin Nutr*. 1999;69:419–425.

66. Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Burke V, Croft KD, Rogers PB. Effects of isoflavonoids on blood pressure in subjects with high-normal ambulatory blood pressure levels: a randomized controlled trial. *Am J Hypertens*. 1999;12:47–53.
67. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Ann Intern Med*. 2002;137:805–813.
68. Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. *Climacteric*. 2000;3:161–167.
69. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. *Climacteric*. 2001;4:13–18.
70. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. *Menopause*. 2002;9:329–334.
71. Burke GL, Legault C, Anthony M, Bland DR, Morgan TM, Naughton MJ, Leggett K, Washburn SA, Vitolins MZ. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. *Menopause*. 2003;10:147–153.
72. Secreto G, Chiechi LM, Amadori A, Miceli R, Venturelli E, Valerio T, Marubini E. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. *Maturitas*. 2004;47:11–20.
73. St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. *Menopause*. 2001;8:17–26.
74. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. *Am J Clin Nutr*. 2003;78:593S–609S.
75. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr*. 1998;68:1375S–1379S.
76. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. *Am J Clin Nutr*. 2000;72:844–852.
77. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. *J Clin Endocrinol Metab*. 2003;88:4740–4747.
78. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. *J Bone Miner Res*. 2002;17:1904–1912.
79. Hsu CS, Shen WW, Hsueh YM, Yeh SL. Soy isoflavone supplementation in postmenopausal women: effects on plasma lipids, antioxidant enzyme activities and bone density. *J Reprod Med*. 2001;46:221–226.
80. Nikander E, Metsa-Heikkilä M, Ylikorkala O, Tiitinen A. Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. *J Clin Endocrinol Metab*. 2004;89:1207–1212.
81. Yamori Y, Moriguchi EH, Teramoto T, Miura A, Fukui Y, Honda KI, Fukui M, Nara Y, Taira K, Moriguchi Y. Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study. *J Am Coll Nutr*. 2002;21:560–563.
82. Chiechi LM, Secreto G, D'Amore M, Fanelli M, Venturelli E, Cantatore F, Valerio T, Laselva G, Loizzi P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. *Maturitas*. 2002;42:295–300.
83. Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME, Arjmandi BH. Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. *J Nutr*. 2002;132:2605–2608.
84. Register TC, Jayo MJ, Anthony MS. Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. *J Clin Endocrinol Metab*. 2003;88:4362–4370.
85. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk: review of the epidemiological evidence. *Breast Cancer Res Treat*. 2003;77:171–183.
86. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. *Cancer Invest*. 2003;21:744–757.
87. Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. *Br J Nutr*. 2004;91:513–531.
88. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S, for the Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group. Soy, isoflavones, and breast cancer risk in Japan. *J Natl Cancer Inst*. 2003;95:906–913.
89. Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogens and breast cancer risk. *Am J Clin Nutr*. 2004;79:282–288.
90. Linseisen J, Piller R, Hermann S, Chang-Claude J, for the German Case-Control Study. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. *Int J Cancer*. 2004;110:284–290.
91. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 1996;5:785–794.
92. McMichael-Phillips DF, Harding C, Morton M, Roberts SA, Howell A, Potten CS, Bundred NJ. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. *Am J Clin Nutr*. 1998;68:1431S–1435S.
93. Allred CD, Allred KF, Ju YH, Goepfing TS, Doerge DR, Helferich WG. Soy processing influences growth of estrogen-dependent breast cancer tumors. *Carcinogenesis*. 2004;25:1649–1657.
94. Murata M, Midorikawa K, Koh M, Umezawa K, Kawanishi S. Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. *Biochemistry*. 2004;43:2569–2577.
95. Luijten M, Thomsen AR, van den Berg JA, Wester PW, Verhoef A, Nagelkerke NJ, Adlercreutz H, van Kranen HJ, Piersma AH, Sorensen IK, Rao GN, van Kreijl CF. Effects of soy-derived isoflavones and a high-fat diet on spontaneous mammary tumor development in Tg.NK (MMTV/c-neu) mice. *Nutr Cancer*. 2004;50:46–54.
96. Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes PJ, Waring RH, Kirk CJ. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. *J Clin Endocrinol Metab*. 2004;89:1779–1787.
97. Lamartiniere CA. Timing of exposure and mammary cancer risk. *J Mammary Gland Biol Neoplasia*. 2002;7:67–76.
98. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT, Zheng W. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. *Cancer Epidemiol Biomarkers Prev*. 2001;10:483–488.
99. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. *Carcinogenesis*. 2002;23:1491–1496.
100. Ziegler RG. Phytoestrogens and breast cancer. *Am J Clin Nutr*. 2004;79:183–184.
101. Cassileth BR, Vickers AJ. Soy: an anticancer agent in wide use despite some troubling data. *Cancer Invest*. 2003;21:817–818.
102. Xu WH, Zheng W, Xiang YB, Ruan ZX, Cheng JR, Dai Q, Gao YT, Shu XO. Soy food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. *BMJ*. 2004;328:1285.
103. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. *Am J Epidemiol*. 1997;146:294–306.
104. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. *J Natl Cancer Inst*. 2003;95:1158–1164.
105. Murray MJ, Meyer WR, Lessey BA, Oi RH, DeWire RE, Fritz MA. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. *Menopause*. 2003;10:456–464.
106. Duncan AM, Merz BE, Xu X, Nagel TC, Phipps WR, Kurzer MS. Soy isoflavones exert modest hormonal effects in premenopausal women. *J Clin Endocrinol Metab*. 1999;84:192–197.
107. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. *Climacteric*. 1999;2:85–92.
108. Scambia G, Mango D, Signorile PG, Anselmi Angeli RA, Palena C, Gallo D, Bombardelli E, Morazzoni P, Riva A, Mancuso S. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. *Menopause*. 2000;7:105–111.
109. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. *Menopause*. 2000;7:236–242.

110. Hale GE, Hughes CL, Robboy SJ, Agarwal SK, Bievre M. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. *Menopause*. 2001;8:338–346.
111. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. *Fertil Steril*. 2004;82:145–148, quiz 265.
112. Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. *Prostate*. 2004;59:141–147.
113. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. *Nutr Rev*. 2003;61:117–131.
114. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K, Mori M, Sakauchi F, Washio M, Ito Y, Suzuki K, Wakai K, Tamakoshi A, for the JACC Study Group. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. *Cancer Sci*. 2004;95:65–71.
115. Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ. Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. *Clin Cancer Res*. 2003;9:3282–3287.
116. Urban D, Irwin W, Kirk M, Markiewicz MA, Myers R, Smith M, Weiss H, Grizzle WE, Barnes S. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. *J Urol*. 2001;165:294–300.
117. Jenkins DJ, Kendall CW, D'Costa MA, Jackson CJ, Vidgen E, Singer W, Silverman JA, Koumbridis G, Honey J, Rao AV, Fleshner N, Klotz L. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. *J Urol*. 2003;169:507–511.
118. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Stroke*. 2000;31:2751–2766.
119. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. *JAMA*. 2003;290:502–510.